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Background: When differential diagnosis is difficult in thyroid follicular lesions with overlapping 
histological features, the immunohistochemical staining can help confirm the diagnosis. We 
aimed to evaluate the effectiveness of rapid immunohistochemical stains of CD56 and cytokeratin 
19 on frozen sections of thyroid follicular lesion and explore the possible gains and limitations of 
the practice. Methods: Eighty-six nodules of 79 patients whose intraoperative frozen sections were 
selected as the control group, and 53 nodules of 48 patients whose intraoperative frozen sections 
were subject to rapid immunohistochemistry were selected as the study group. Results: Five 
nodules (6%) in the control group were diagnosed as follicular neoplasm and six nodules (7%) 
were deferred. In the study group, six nodules (11%) were follicular neoplasm and none were deferred. 
Three nodules (4%) in the control group showed diagnostic discrepancy between the frozen and 
permanent diagnoses, but none in the study group. The average turnaround time for the frozen 
diagnosis of the control group was 24 minutes, whereas it was 54 minutes for the study group. 
Conclusions: Intraoperative rapid immunohistochemical stains significantly decreased the diagnostic 
discrepancy in this study. Considering the adverse effects of indefinite frozen diagnosis or discrep-
ancy with permanent diagnoses, the intraoperative rapid immunohistochemical stain can help to 
accurately diagnose and hence provide guidance to surgical treatment.
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▒ ORIGINAL ARTICLE ▒
Follicular patterned lesions of the thyroid impose not so trivial 
diagnostic difficulty because the cytological features can be deceiving 
and the diagnosis of malignancy depends on non-disputable 
histologic evidence other than morphologic criteria.1 Thus, unlike 
other tumors, a limited number of representative sections of the 
lesion cannot be relied upon for an accurate diagnosis, and the 
diagnostic accuracy of fine needle aspiration and intraoperative 
frozen diagnosis are often compromised.2 Moreover, it is not 
surprising to find that even thyroid experts have discrepancy in 
the diagnosis of follicular lesions, harboring the entire spectrum 
of benign to malignant tumors,3-6 and yet, an accurate diagnosis 
is just as important for the follicular patterned lesions as for other 
tumors because treatment plans totally depend on the pathologic 
diagnosis. As such, there have been efforts to more actively utilize 
core biopsy in the diagnosis of thyroid lesions with expectations 
that immunohistochemical (IHC) stains will aid in more accurate 
diagnosis.7-9 However, we must not overlook the fact that IHC 
stains in follicular patterned lesions can vary from area to area,10 
and so the IHC stain results in the core biopsy can be more often 
misleading than not. We also should consider the fact that for 
follicular neoplasm, a key to the diagnosis is the presence or absence 
of a complete capsule of the entire lesion,1 which can never be 
accurately assessed by core biopsy alone, irrespective of the IHC 
stain results. These limitations in the preoperative diagnosis of 
the follicular patterned lesions naturally lead to the conclusion 
that at present, there is no alternative other than assessing the 
histology of the entire lesion in cases of follicular patterned lesions. 
However, we propose that if not preoperatively, we can at least 
aid in making surgical decision intraoperatively by applying 
IHC stain to frozen section. Even though differential diagnosis 
of the follicular neoplasm and follicular variant papillary thyroid 
carcinoma (FVPTC) is difficult on frozen sections, shedding 
light on the more possible diagnosis between the two is plausible 
by frozen section and it can be an aid enough for the surgeon. 
We propose that IHC stains that are ancillary in the differential 
diagnosis of follicular neoplasm and FVPTC can also be applied 
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.05.25
464     •  Pyo JY, et al.
to the frozen section intraoperatively, and among many that are 
used in permanent sections, we chose CD56 and cytokeratin 19 
(CK19) based on our past experiences. We aimed to evaluate 
the exact positive yields of the IHC stains on intraoperative frozen 
sections and explore the possible gains and limitations of the 
practice. 
MATERIALS AND METHODS
Patients and nodules
Eighty-six nodules of 79 patients whose intraoperative frozen 
sections were not subject to IHC stains at all were selected as 
the control group (Fig. 1A) and 53 nodules of 48 patients whose 
intraoperative frozen sections could be subject to IHC stains if 
necessary were selected as the study group (Fig. 1B). For each group, 
the study duration was about a month. This study was approved by 
the Institutional Review Board of Gangnam Severance Hospital 
with a waiver of informed consent (IRB No. 3-2015-0133).
Rapid IHC stain 
Fresh frozen tissue in OCT compound was sectioned with 
Cryo-cut Microtome (Leica Biosystems, Newcastle Upon Tyne, 
UK) in 3–4 μm thickness, placed on silane coated slide, and let 
dry. The slide was then stained for rapid immunohistochemistry 
in LEICA BOND-III Autostainer using Bond Polymer Refine 
Detection kit (Leica Biosystems). Briefly, the dry slide was fixed 
in 4% paraformaldehyde for 1 minute, immersed in peroxide 
block for 2 minutes to endogenous peroxidase blocking, washed 
and then applied with primary antibody for 4 minutes. After 
washing with Bond Wash solution, the slide was sequentially 
applied with post primary agent for 2 minutes and polymer for 
2 minutes with washings in-between. The antibodies used were 
CK19 (1:80, RCK108, mouse monoclonal, DAKO, Carpinteria, 
CA, USA) and CD56 (1:50, 123C3, mouse monoclonal, DAKO). 
They were detected with 3,3’-diaminobenzidine (DAB) chromogen 
and DAB enhancer and counterstained with hematoxylin. The 
entire process takes roughly about 30 minutes. 
Microscopic evaluation
Nodules of the control group were intraoperatively diagnosed 
based on the hematoxylin and eosin (H&E) findings alone and 
the total amount of time spent on the diagnosis, so-called turn-
around time, was recorded. Nodules of the study group were subject 
to IHC stains for CD56 and CK19 only when the diagnosis 
could not be reached on H&E findings alone. When H&E findings 
were informative enough for definitive diagnosis, IHC stains 
were not performed and the turnaround time was recorded. 
According to El Demellawy et al.,11 membranous staining of 
follicular epithelial cells for CD56 (≥ 10% cut-off) was considered 
positive. As shown in the diagnostic algorithm of Fig. 1B, those 
lesions showing cytological features suspicious for, but not diag-
nostic of, papillary thyroid carcinoma (PTC) were subject to IHC 
stains, and PTC was diagnosed when the suspicious cells were 
CD56-negative and CK19-positive (Fig. 2A–C). When the sus-
picious cells were CD56-positive, however, the diagnosis of either 
follicular neoplasm (Fig. 2D–F) or adenomatous hyperplasia (Fig. 
2G–I) was reached.11-13 These diagnoses were based upon consul-
tation to an experienced thyroid pathologist (S.W. Hong). The 
turnaround time was recorded after the IHC stains for the study 
group. For the control group, the frozen diagnoses were deferred 
when the histological or cytological features of the nodules were 
equivocal or when the histological features were suspicious of follic-
ular neoplasm (Fig. 1A). The intraoperative diagnoses were clas-
sified as benign, malignant, follicular neoplasm, and deferred. 
The number of lesions showing discrepancy between the frozen 
diagnosis and permanent diagnosis and the type of discrepancy 
were evaluated in those that were not deferred in the intraoper-
ative diagnosis. Final diagnoses on the permanent sections of the 
deferred lesions and those that were reported as follicular neoplasm 
intraoperatively were also evaluated. 
Statistical analysis
The type of intraoperative diagnosis, the number of discrepancy 
between the frozen diagnosis and the final permanent diagnosis, 
and the turnaround time in the intraoperative diagnosis of the 
two groups were analyzed by Student’s t test and Fisher exact 
test. Statistical analysis of data was performed using the SPSS 
software ver. 17.0 (SPSS Inc., Chicago, IL, USA). The p-value 
less than .05 were considered statistically significant.
RESULTS
Seventy-nine patients allocated to the control group consisted 
of 14 men and 65 women. Forty-eight patients in the study 
group consisted of eight men and 40 women. The clinicopatho-
logic characteristics in two groups were tabulated (Table 1). There 
was no significant statistical difference in the distribution of gender 
and age between the two groups. A total of 84 nodules out of 
86 in the control group (98%) were diagnosed within 40 minutes 
and only two nodules (2%) were diagnosed after 40 minutes. The 
turnaround time of 40 minutes was agreed to be a reasonable 
cutoff by the departments of pathology and surgery, considering 
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Fig. 1. Diagnostic algorithm of thyroid follicular patterned lesions on frozen section. (A) Control group. (B) Study group. H&E, hematoxylin 
and eosin; IHC, immunohisteochemisty; CK19, cytokeratin 19.
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the time required to construct one block of typical frozen section 
and the time required for rapid IHC. This is in line with the 
guidelines recommended by the Joint Commission of Interna-
tional Certification and the guidelines for quality management of 
the Korean Society of Pathologists. For frozen sections without 
immunostaining, the turnaround time was kept within 15 min-
utes to 20 minutes. The average turnaround time to diagnosis 
was 24 minutes for the control group. For the study group, 17 
out of 53 nodules (32%) were diagnosed within 40 minutes and 
36 nodules (68%) were diagnosed after 40 minutes (p < .000). 
The average turnaround time for the study group was 57 minutes 
(Table 1). As for the type of intraoperative frozen diagnosis, in 
75 out of 86 nodules of the control group (87%) and 47 out of 
53 nodules of the study group (89%), a clear definite diagnosis 
was possible. Five out of 86 nodules in the control group (6%) 
were diagnosed as follicular neoplasm, and six nodules (7%) were 
deferred. In contrast, six nodules out of 53 in the study group 
(11%) were diagnosed as follicular neoplasm, and none were 
deferred. There was no significant statistical difference in the 
distribution of intraoperative frozen diagnosis between the two 
groups (Table 1). 
With respect to the diagnostic discrepancy between frozen 
diagnosis and permanent diagnosis in the two groups, three 
nodules out of 75 (4%) in the control group showed discrepancy 
A
D
G
B
E
H
C
F
I
Fig. 2. Histologic and immunohistochemical features of thyroid follicular lesions. (A) Frozen section of follicular patterned lesion reported as fol-
licular variant papillary carcinoma. (B) Immunohistochemical stain for CD56 showing diffuse negative reaction in the tumor cells as opposed 
to the adjacent normal thyroid tissue. (C) Immunohistochemical stain for cytokeratin 19 (CK19) showing diffuse strong positive reaction in the 
tumor cells. (D) Frozen section of follicular patterned lesion reported as follicular neoplasm. (E) Immunohistochemical stain for CD56 showing 
diffuse positive reaction in the tumor cells as opposed to the adjacent normal thyroid tissue. (F) Immunohistochemical stain for CK19 show-
ing diffuse negative reaction. (G) Frozen section of follicular patterned lesion reported as adenomatous hyperplasia. (H) Immunohistochemical 
stain for CD56 showing multifocal patchy positive reaction in the tumor cells and the adjacent normal thyroid tissue as well. (I) Immunohisto-
chemical stain for CK19 showing positive reaction in the adjacent normal thyroid and also in a few tumor cells though much attenuated.
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in the diagnosis; two cases were initially diagnosed as adenomatous 
hyperplasia and lymphocytic thyroiditis on frozen sections, and 
then as conventional PTC and noninvasive capsulated FVPTC on 
permanent sections (discrepancy rate, 0.087); and one nodule was 
initially diagnosed as conventional PTC on frozen section, and 
then as lymphocytic thyroiditis on permanent section (discrepan-
cy rate, 0.019). None of the study group had discrepancy between 
the frozen and permanent diagnoses (discrepancy rate, 0). Although 
they are not classified as a discrepancy, six malignant nodules in 
the control group turned out to be different histologic types in 
permanent sections (Table 2). In the control group, two out of five 
follicular neoplasms on frozen section turned out to be FVPTC on 
permanent sections. In the study group, two out of six follicular 
neoplasms on frozen section were diagnosed as oncocytic variant 
PTC and noninvasive capsulated FVPTC on permanent sections, 
due to different nuclear features and IHC profiles on permanent 
sections (Table 3). Four out of six deferred nodules of the control 
group were revealed to be FVPTC on permanent diagnosis (malig-
nancy rate, 0.667) (Table 4). Immunophenotypes of 36 nodules in 
the study group are summarized in Table 5. All of nine nodules 
(CK19+, CD56+) were immunohistochemically matched with 
benign on permanent diagnosis, and all of 15 nodules (CK19+, 
CD56–) were matched with conventional PTC. Two nodules 
which were initially diagnosed as follicular neoplasm due to the 
Table 1. Clinicopathologic features of the control group and the 
study group
Parameter Control group Study group p-value
Sex (man:woman)a 14:65 (18:82) 8:40 (17:83) 1.000b
Age, mean (range, yr)a 49 (24–75) 45 (24–68) .258c
   Man 50 (32–75) 54 (41–68)
   Woman 47 (24–70) 44 (24–64)
Turnaround time (min)d
   Mean 24 57 .000b
   < 40 min 84 (98) 17 (32) 
   ≥ 40 min 2 (2) 36 (68)
Frozen diagnosisd .149b
   Benign 23 (27) 12 (23)
      AH 20 (23) 8 (15)
      LT 3 (4) 4 (7)
   Malignancy 52 (60) 35 (66)
      PTC, conventional 43 (50) 29 (55)
      FVPTC 7 (8) 4 (7)
      PTC, oncocytic variant 1 (1) 0 
      HC 0 1 (2)
      FC 1 (1) 1 (2)
   Follicular neoplasm 5 (6) 6 (11)
   Deferred 6 (7) 0 
Values are presented as number (%), unless otherwise indicated.
AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; PTC, papillary 
thyroid carcinoma; FVPTC, follicular variant papillary thyroid carcinoma; 
HC, Hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive.
aNumber of patients: control (n = 79), study group (n = 48); bFisher exact 
test; ct test; dNumber of nodules: control (n  =  86), study group (n  =  53).
Table 2. Diagnostic discrepancy between frozen and permanent diagnoses in each group
Frozen diagnosis 
(No. of nodules)
Permanent diagnosis (No. of nodules)
Discrepancy rate
Benign Malignant
AH LT PTCc
FVPTC
cap+, inv-
FVPTC
cap+, inv+
FVPTC
cap-
HC FC
Control group
   Benign (n = 23) 0.087
      AH 19 0 1 0 0 0 0 0
      LT 0 2 0 1 0 0 0 0
   Malignant (n = 52) 0.019
      PTCc 0 1 38 0 1 2 1 0
      FVPTC 0 0 0 0 0 6 0 1
      HC 0 0 0 0 0 0 0 0
      FC 0 0 0 1 0 0 0 0
Study group
   Benign (n = 12) 0
      AH 8 0 0 0 0 0 0 0
      LT 0 4 0 0 0 0 0 0
   Malignant (n = 35) 0
      PTCc 0 0 29 0 0 0 0 0
      FVPTC 0 0 0 1 3 0 0 0
      HC 0 0 0 0 0 0 1 0
      FC 0 0 0 0 0 0 0 1
AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; PTCc, papillary thyroid carcinoma, conventional; FVPTC, follicular variant papillary thyroid carcino-
ma; cap+, capsule present; inv-, no capsule invasion; inv+, capsule invasion present; cap-, no capsule; HC, Hurthle cell carcinoma; FC, follicular carcinoma, 
minimally invasive.
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IHC staining results of CK19– and CD56+ were finally diagnosed 
as oncocytic variant PTC in one and FVPTC in the other; the 
IHC stain results were reversed to CK19+ and CD56– on perma-
nent sections.
DISCUSSION
Application of IHC to frozen sections can diminish critical 
diagnostic discrepancy between the intraoperative frozen diagnosis 
and subsequent permanent diagnosis. In our study, those that 
were not subject to IHC on frozen sections showed a diagnostic 
discrepancy in 4%, a change in histologic subtype of malignant 
nodules in 11%, and a diagnostic deferral in 7%. In those with a 
diagnostic discrepancy, for example, FVPTC was misdiagnosed as 
lymphocytic thyroiditis intraoperatively, lymphocytic thyroiditis 
was mistaken for conventional PTC, and conventional PTC was 
missed due to a sampling error. In addition, six out of 52 malignant 
nodules in the control group showed altered histological subtypes, 
but there was no difference in the 35 malignant nodules of the 
study group. Most of the deferred lesions and lesions of follicular 
neoplasm were finally diagnosed as capsulated FVPTC. However, 
those to which IHC was applied intraoperatively did not have 
any diagnostic discrepancy and none of them were deferred.
With the introduction of FVPTC in 1977,14 many cases previ-
ously thought to be follicular neoplasm were confirmed to be, in 
fact, FVPTC. This has led to a rather increased frequency of intra-
Table 5. Immunophenotypes of the study group nodules that were subject to rapid immunohistochemical stain 
Immunophenotype
Permanent diagnosis (No. of nodules)
Total No. of nodules 
(n  =  36)
Benign (n  =  15) Malignant (n  =  21)
AH LT FA HA FC HC PTCc PTCo FVPTC
CK19+/CD56+ 6 3 0 0 0 0 0 0 0 9
CK19–/CD56+ 3 0 2 1 1 1 0 0 0 8
CK19+/CD56– 0 0 0 0 0 0 15 1a 3a 19
CK19–/CD56– 0 0 0 0 0 0 0 0 0 0
AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; FA, follicular adenoma; HA, hurthle cell adenoma; FC, follicular carcinoma, minimally invasive; HC, 
hurthle cell carcinoma; PTCc, papillary thyroid carcinoma, conventional; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular variant of 
papillary thyroid carcinom.
aAlthough it showed CD56 positivity and cytokeratin 19 (CK19) negativity on rapid immunohistochemical stain of frozen section, focal loss of CD56 and focal 
reactivity of CK19 were revealed on permanent section of remained lesion.
Table 4. Malignancy rate of deferred lesion between frozen and permanent diagnoses in each group
Frozen diagnosis
(deffered)
Permanent diagnosis (No. of nodules)
Malignancy 
rate
Benign (n = 2) Malignant (n = 4)
FA HA AH PTCo
FVPTC
cap+, inv-
FVPTC
cap+, inv+
HC FC
Control group 1 0 1 0 4 0 0 0 0.667
Study group 0 0 0 0 0 0 0 0 0
FA, follicular adenoma; HA, hurthle cell adenoma; AH, adenomatous hyperplasia; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular vari-
ant of papillary thyroid carcinoma; cap+, tumor capsule present; inv-, no capsule invasion; inv+, capsule invasion present; HC, hurthle cell carcinoma; FC, fol-
licular carcinoma, minimally invasive.
Table 3. Malignancy rate of FN between frozen and permanent diagnoses in each group
FN at frozen diagnosis 
(No. of nodules)
Permanent diagnosis (No. of nodules)
Malignancy 
rate
Follicular neoplasm Other
Benign Malignant
Total AH PTCo
FVPTC
cap+, inv-
FVPTC
cap+, inv+
Total 
FA HA HC FC
Control group (n = 5) 1 0 1 1 3 (60) 0 0 1 1 2 (40) 0.800
Study group (n = 6) 2 1 0 0 3 (50) 1 1a 1a 0 3 (50) 0.333
Values are presented as number (%).
FN, follicular neoplasm; FA, follicular adenoma; HA, hurthle cell adenoma; HC, hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive; AH, adeno-
matous hyperplasia; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; cap+, tumor capsule present; 
inv-, no capsule invasion; inv+, capsule invasion present.
aAlthough it showed CD56 positivity and cytokeratin 19 (CK19) negativity on rapid immunohistochemical stain of frozen section, focal loss of CD56 and focal 
reactivity of CK19 were revealed on permanent section of remained lesion.
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operative pathologic consultation by frozen section in cases that 
had been preoperatively diagnosed as follicular neoplasm or 
reported to have some degree of nuclear atypia. Of course, these 
cases cannot be definitively diagnosed on frozen sections and 
they require meticulous sampling and ancillary IHC stain on 
permanent sections to reach definitive diagnosis.11-13 To our 
knowledge, there has not yet been any report in thyroid lesions 
that employed the use of IHC in the intraoperative frozen diagnosis. 
Follicular neoplasm, by definition, cannot be a candidate for frozen 
diagnosis because its diagnosis depends on the histologic exami-
nation of the entire capsule of the mass.15 However, as FVPTC 
has entered the diagnostic spectrum, a possible follicular neoplasm 
has also become a candidate for frozen diagnosis in order to rule 
out the possibility of FVPTC16 which, in contrast to the follicular 
neoplasm, can be diagnosed on representative sections of the 
mass like other PTCs. At this point, we should note that considering 
the morphologic and gross features of FVPTC, there is always a 
hindrance of misinterpreting the microscopic appearance on frozen 
sections due to frozen artifacts.17 In our institution, we have an 
experience of detecting micrometastasis in lymph nodes of 
breast cancer patients by applying IHC stain for cytokeratin on 
frozen sections.18 With this previous experience, we applied IHC 
on frozen sections of the thyroid follicular lesions, expecting to 
distinguish between malignant and benign lesions intraoperatively 
and hence minimize the number of deferred or misdiagnosed 
lesions.
Many antibodies are now being used in the diagnosis of 
FVPTC,11-13 but we chose CD56 and CK19 based on the integrated 
results of many antibodies and our accumulated experience here-
tofore. The combined results of CD56 negativity and CK19 posi-
tivity can maximize the diagnosis of PTC. Moreover, in contrast 
to HBME1, CK19 is often positive not only in PTC but also in 
adenomatous hyperplasia as well,11-13 and this has led us to integrate 
the staining patterns of the two antibodies in the differential diagnosis 
of follicular patterned lesions. In our study, we could definitely 
diagnose PTC and FVPTC in follicular patterned lesions showing 
atypical nuclear features with a constant IHC staining pattern of 
CK19+ and CD56–. On the other hand, we could avoid overdi-
agnosis by confirming an IHC staining pattern of CK19+ and 
CD56+ in benign follicular lesions such as lymphocytic thyroiditis, 
even with nuclear atypia.
The study group showed a longer turnaround time, which 
was 33 minutes longer than that of the control group in average, 
and 68% of them took more than 40 minutes in the diagnosis. 
However, we should consider the total cost and psychological 
trauma of patients in the control group whose diagnoses were deferred 
(7%) or discrepant (4%). The time taken in IHC staining can be 
shortened to some extent although limited, but we expect to 
shorten the turnaround time more effectively if only we can decide 
with more speed whether the case in hand needs IHC on frozen 
section or not. 
Most of the nodules diagnosed as follicular neoplasm were finally 
diagnosed as FVPTC. Four out of five nodules of the control 
group were diagnosed as follicular carcinoma in one, hurthle cell 
carcinoma in one, and as encapsulated FVPTC in two nodules 
with or without capsular invasion. In contrast, only one out of 
six nodules diagnosed as follicular neoplasm in the study group 
was finally diagnosed as noninvasive encapsulated FVPTC after 
an additional IHC staining and further evaluation of permanent 
sections. The other nodule was diagnosed as oncocytic PTC after 
further evaluation of the remaining specimen. 
Deferred lesions or lesions of follicular neoplasm that are finally 
confirmed to be malignant on permanent sections need to undergo 
secondary surgical procedure or other additional treatment. As 
such, we should note that 80% of the follicular neoplasms and 67% 
of the deferred lesions in the control group were finally confirmed to 
be malignant, whereas 33% of the follicular neoplasms in the 
study group were finally confirmed to be malignant. In the control 
group, two patients diagnosed with follicular neoplasm underwent 
completion thyroidectomy and two times of radioiodine treatment. 
Three patients whose frozen diagnoses were deferred underwent 
additional radioiodine treatment. On the other hand, three patients 
in the study group, diagnosed as FVPTC (n = 2) and lymphocytic 
thyroiditis (n = 1), avoided secondary surgical procedure. 
We do have two nodules (3.7%) in the study group that could 
not be diagnosed even with the aid of IHC, which is only natural 
because patterns of immunoexpression in FVPTC can vary even 
in permanent sections.11-13 But, if we consider the fact that the 
number escalates to six (7.0%) in the control group without the 
aid of IHC, we can safely say that the IHC can make a rather 
significant difference in the accuracy of frozen diagnosis in follicular 
patterned lesions. Therefore, we propose that if more specific 
antibodies are selected and applied, an intraoperative IHC stain 
on frozen sections can significantly improve the diagnostic accuracy 
in thyroid follicular lesions. 
In conclusion, although the significance of intraoperative IHC 
stain is somewhat compromised by longer turnaround time, it 
considerably diminishes the diagnostic discrepancy and inaccuracy. 
With consideration of the adverse effects of indefinite intraoper-
ative diagnosis or discrepancy between the frozen and permanent 
diagnoses incurred on the patients, a development of more specific 
antibodies is necessary and their application to the intraoperative 
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diagnosis of thyroid follicular lesions will further increase the 
diagnostic accuracy.
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